A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Tesetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Jul 2012 Additional lead investigator (Tina Mayer) added as reported by ClinicalTrials.gov.
- 11 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.